BridgeBio doses first participant in ASCEND-ATTR Phase 3b/4 study
BridgeBio said the first participant was dosed in its Phase 3b/4 ASCEND-ATTR study evaluating acoramidis on disease regression in ATTR-CM.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.